Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pyrukynd
Fierce Biotech
Agios shedding 100 R&D roles ahead of hoped-for SCD approval
Agios has been shrinking its R&D headcount throughout 2026 as the commercial-stage company looks to shed more than 100 roles by year-end.
James Waldron
Nov 5, 2026 8:40am
Agios’ Pyrukynd turns in mixed results in sickle cell ph. 3
Nov 19, 2025 12:00pm
Agios' Pyrukynd misses the mark in first pediatric study
Aug 1, 2024 1:08pm
Agios charts broad path for oral thalassemia med after trial win
Jan 3, 2024 10:49am
Agios' first-in-class PK activator Pyrukynd scores FDA nod
Feb 17, 2022 4:50pm